To evaluate changes in anti-glycemic treatment patterns in patients newly augmenting statin therapy with niacin extended-release (NERϩS), relative to patients initiating alternative lipid regimens. METHODS: An observational cohort study was conducted using integrated administrative claims and laboratory result data within the HealthCore Integrated Research Database. T2DM patients aged 18 to 64 initiating statin-augmenting therapy (NERϩS, ezetimibe (EZEϩS), or fenofibrate (FFBϩS)) or statin monotherapy (SM) between 1/1/2005-11/30/2008 (index date) were included. Patients with Ն12 months of pre-index eligibility and Ն1 laboratory result for hemoglobin A1c (HbA1c) within the 12-month period were included. The utilization and average daily dose (ADD) of anti-glycemic medications during the 12-month pre-index and follow-up period were compared between cohorts. RESULTS: A total of 42,250 patients were identified: 2,041 NERϩS, 6,915 EZEϩS, 3,095 FFBϩS, and 30,199 SM. Compared to each cohort, NERϩS patients were more likely to be male (PϽ0.0001), and have higher prevalence of preexisting ischemic heart conditions (PϽ0.0001). NERϩS patients had lowest preindex total cholesterol (174.3 Ϯ 55.2; PϽ0.0001), HDL-C (37.2 Ϯ 10.1; PϽ0.0001), second lowest LDL-C (93.7 Ϯ 38.4), and second highest TG (245.3 Ϯ 307.0) prior to the index date. Among oral anti-glycemic therapies, NERϩS patients were observed to have the largest decrease in ADD (mg/day) for biguanides (metformin: -155.9 Ϯ 788.0; PϽ0.0001), sulfonylureas (glimepiride: -0.1 Ϯ 1.9; P ϭ 0.0053; glipizide: -0.8 Ϯ 20.8; P Ͻ .0001), TZD's (pioglitizone: -0.8 Ϯ 8.2; P ϭ 0.0210), and incretin mimetic agents (exenatide: -0.1 Ϯ 3.5; P ϭ 0.0012) from pre-index to follow-up. Furthermore, NERϩS patients had the smallest increase in ADD of DPP-4's (sitagliptin: 0.3 Ϯ 17.6; P ϭ 0.0067). CONCLUSIONS: Despite studies indicating the potential for NER to antagonize glycemic control among T2DM patients, patients initiating NERϩS were observed to have decreased utilization and average daily dose of anti-glycemic medications, relative to alternative treatment regimens.
OBJECTIVES:
To compare medication treatment and 12-month outcomes of patients aged Ͻ75 and Ն 75 years who have acute coronary syndromes (ACS) and who have undergone percutaneous coronary intervention (PCI). METHODS: Data were from APTOR, robust, prospective, observational registries from 14 European countries from [2007] [2008] [2009] . Kaplan-Meier (KM) estimates at 12-months post-PCI were calculated for cardiovascular (CV) event (unstable angina [UA] , non-ST-elevation myocardial infarction [NSTEMI] , STEMI, urgent target vessel revascularization, acute heart failure, ischemic and hemorrhagic strokes or CV death), bleeding, and mortality by age. RESULTS: 82% were Ͻ75 years (Nϭ3742, median age: 59) and 18% were Ն75 years (Nϭ803, median age: 79). Older patients tended to be women (38% vs. 20%); to weigh Ͻ60kg (10% vs. 4%); have more hypertension (72% vs. 54%) and diabetes (26% vs. 20%); have prior MI (28% vs. 18%) and PCI (22% vs. 17%). For older/younger patients, respectively, the ACS presentation was 25%/22% for UA, 39%/29% for NSTEMI, and 36%/49% for STEMI; treatment at PCI was 14%/10% for clopidogrel loading doses Ͻ300 mg, 24%/33% for GPIIb/IIIa inhibitors, and 5% /11% for thrombolytic/fibrinolytic therapy. KM (95% CI) estimates for older and younger patients, respectively, were: 19.8% (17.0%, 22.6%) vs. 13.4% (12.3%, 14.5%) for CV event, 3.7% (2.4%, 5.1%) vs. 2.6% (2.1%, 3.1%) for bleeding, and 6.8% (5.0%, 8.5%) vs. 1.5% (1.1%, 1.9%) for mortality. CONCLUSIONS: Older patients tended to receive GPIIb/IIIa and thrombolytic/fibrinolytic therapy less frequently at PCI, contributing to comparable bleeding rates. However, the higher post-discharge ischemic event rates suggest that the risk/benefit ratios in the elderly may need to be considered more carefully. One strategy might be that, if revascularisation is proposed in older ACS patients, those at lower bleeding risk be treated more aggressively with potent, newer peri/postprocedural, antiplatelet/antithrombotic management to balance the post-PCI outcomes disparity at 12 months.
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DIFFERENCES IN THE WEIGHTED AVERAGE DAILY DOSES OF STATINS IN EUROPE AND THEIR POTENTIAL IMPACT ON CARDIOVASCULAR OUTCOMES
Liew D, Webb K The University of Melbourne, Parkville, Victoria, Australia OBJECTIVES: Market data indicate that simvastatin and atorvastatin, which will soon come off patent, are prescribed at non-equipotent doses across Europe. We sought to estimate the differential effects of this on low-density lipoprotein cholesterol (LDL-C) levels and risk of cardiovascular events. METHODS: Weighted average daily doses (WADDs) of prescribed simvastatin and atorvastatin in 16 Western European countries were derived from IMS data for 2010. Dose-specific, LDL-C modifying potencies of the 2 statins were derived from the meta-analysis by Nich-olls et al (Am J Cardiol, 2010) . The relationship between reduction in LDL-C achieved by statin therapy and impact risk of cardiovascular events was derived from the meta-regression by the Cholesterol Treatment Trialists' Collaboration (Lancet, 2010) . This showed that for every 1mmol/L reduction in LDL-C, the relative risk for a major cardiovascular (coronary and/or stroke) event was 0.78 (95%CI 0.76-0.80). RESULTS: Across the 16 Western European countries, the WADDs for simvastatin and atorvastatin were 28.2mg and 24.4mg, respectively. The corresponding relative reductions in LDL-C at these doses would be 35.8% and 42.0%. Assuming a pre-treatment LDL-C of 4.0mml/L, these lipid changes would lead to relative reductions in the risk of a major cardiovascular event of 31.5% and 37.0%, respectively. In each of the major markets of France, the The Netherlands, Spain, the UK and Italy, atorvastatin was prescribed at a higher equivalent dose than simvastatin. Hence it is likely to confer greater potential population cardiovascular benefits. CONCLUSIONS: In Western Europe, atorvastatin is prescribed at a higher equivalent dose than simvastatin. The significant advantages of atorvastatin over simvastatin in terms of LDL-C and cardiovascular risk reduction will be further enhanced when acquisition prices for atorvastatin fall after its impending loss of exclusivity.
PCV13 COMPARING THE EFFECTIVENESS OF ROSUVASTATIN AND ATORVASTATIN IN PREVENTING CARDIOVASCULAR EVENTS FOR POPULATIONS STRATIFIED BY BASELINE CARDIOVASCULAR RISK: ESTIMATES USING THE ARCHIMEDES MODEL
Schuetz CA 1 , Van herick A 1 , Alperin PE 1 , Peskin BR 1 , Hsia J 2 , Gandhi SK 2 1 Archimedes, Inc., San Francisco, CA, USA, 2 AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA OBJECTIVES: This study estimated the effectiveness of rosuvastatin 20mg (R20) versus atorvastatin 40mg (A40) and 80mg (A80), and rosuvastatin 40mg (R40) versus A80 in preventing clinical events in several higher cardiovascular-risk patient populations using simulation. METHODS: The Archimedes Model was used to simulate head-to-head clinical trials in several populations based on 10-year Framingham risk score (FRS) levels (Ͻ10, 10-20, Ͼ20) and EURO-SCORE (Ͻ5, Ͼ5) to estimate the occurrence of MACE (comprising MI, stroke, and cardiovascular death). Simulated patients ages 45-70 with FRS Ͼ5% were drawn from the National Health and Nutrition Examination Survey. Treatment models were validated using biomarker/ outcomes data from published trials. RESULTS: The patient numbers in each FRS and EURO-SCORE level population ranged from 9190 to 38,313. R20 reduced MACE more than A40 or A80 and R40 more than A80 in all scenarios, with higher risk subgroups showing greater absolute benefit. The 5-year number needed to treat (NNT) to prevent a MACE event for R40 versus A80 for EURO-SCORE Ͻ5, and Ͼ5 were 352 and 154 for 5 years and 154 and 72 for 10 years, respectively. The 5-year relative risk (RR) of MACE for R20 versus A40 was approximately 0.9, irrespective of baseline risk. The 5-year RR of MACE for R20 versus A80 ranged from 0.92 to 0.94, and for R40 versus A80 it was 0.88 to 0.90. RR estimates were similar at 10 and 20 years; however, NNT decreased over time. CONCLUSIONS: The Model estimated that R20 lowers the risk of MACE more than A40 or A80, and R40 further lowers risk compared with A80. The estimated absolute risk reduction with rosuvastatin was greater with higher baseline risk and over time. While simulation models cannot replace controlled clinical trials, this study highlights the potential of using rigorous modeling approaches to bridge evidence gaps.
PCV14 MIXED TREATMENT COMPARISON OF DRONEDARONE, AMIODARONE AND SOTALOL FOR THE MANAGEMENT OF ATRIAL FIBRILLATION IN AUSTRALIA
Badcock CA 1 , Lee J 2 , Gonzalo F 3 1 Statistical Revelations Pty Ltd, Black Rock North, Victoria, Australia, 2 Sanofi Australia Pty Ltd, Macquarie Park, NSW, Australia, 3 Sanofi-Aventis Australia Pty Limited, Macquarie Park, Australia OBJECTIVES: To compare the relative efficacy and tolerability of amiodarone, sotalol and dronedarone for the treatment of atrial fibrillation (AF) in Australia using mixed treatment comparisons (MTC). METHODS: There are limited data directly comparing the safety and effectiveness of dronedarone with the alternatively used antiarrhythmic drugs (AADs) in Australia. In the absence of direct comparisons, we have performed an MTC of networks of trials in order to provide best estimates of the relative effectiveness and safety of the alternative AADs. This approach was previously used by Freemantle et al (2011) to compare dronedarone not only with amiodarone and sotalol, but also with flecainide and propafenone. As flecainide and propafenone are not widely used in Australia, we chose to exclude them from the current analysis. Literature in AF involving amiodarone, dronedarone, sotalol or placebo was searched systematically. The 10 selected trials were combined using MTC models to provide direct and indirect comparisons in a single analysis. Randomised trials with at least one month of treatment and at least 3 months follow up were included. RESULTS: Results are presented versus placebo. Trends towards increased mortality for sotalol (OR 4.67, 95% CI 1.89 -11.57) and amiodarone (OR 2.92, 95% CI 1.17 -7.31) were found. Conversely, a trend towards decreased mortality for dronedarone was found (OR 0.87, 95% CI 0.69 -1.09). CONCLUSIONS: Using an MTC approach of the AADs available in the Australian clinical setting, we have shown that dronedarone is associated with a decrease in the risk of all-cause mortality, and amiodarone and sotalol are associated with an increase in the risk of all-cause mortality.
PCV15 GUIDELINES ADHERENCE AND HYPERTENSION CONTROL IN PATIENTS SUFFERING FROM CARDIOVASCULAR DISEASE
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